Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) for reimbursement as a treatment option for the maintenance treatment (84 day) of relapsed / refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.
This is written in the approval document as:
Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.
Citation
RiTUXimab 375 mg/m2 Maintenance Therapy-84 day, 2021, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/rituximab-375-mg-m2-maintenance-therapy-84-day.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD20 + | Follicular Lymphoma | Rituximab | |
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Rituximab |